아이포인트 파마슈티컬스(EYPT)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.88 (-2.76%), 시가총액 $1.05B, 52주 최저~최고 $5.60 ~ $18.85.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2
아이포인트 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
아이포인트 파마슈티컬스의 현재 주가는 $3.88 (-2.76%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
아이포인트 파마슈티컬스의 시가총액은 약 $1.05B입니다.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Duras